Ulinastatin Inhibits Nasopharyngeal Carcinoma Metastasis by Suppressing uPA/uPAR Signaling

Chang‐Zhi Li, Yuanyuan Qiang, Zhi‐Jie Liu, Lisheng Zheng, Li‐Xia Peng, Yan Mei, Dong‐Fang Meng, Wenwen Wei, Dong-Wen Chen, Liang Xu, Yan‐Hong Lang, Ping Xie, Xing‐Si Peng, Ming‐Dian Wang, Lingling Guo, Dehuan Xie, Ditian Shu, Liuyan Ding, Si‐Ting Lin, Fei‐Fei Luo, Jing Wang, Shasha Li, Bi‐Jun Huang, Jindong Chen, Chao‐Nan QianResearch Square 2021 · DOI

Introduction

Nasopharyngeal Carcinoma (NPC) is a highly invasive malignancy with a particularly high prevalence in Southern China and Southeast Asia. While primary tumors often respond well to radiotherapy, distant metastasis remains the leading cause of treatment failure and mortality. Current therapeutic options for metastatic NPC frequently involve high systemic toxicity, creating an urgent need for "anti-metastatic" agents that can prevent cancer spread without the severe side effects of traditional chemotherapy.

This study investigates the potential of Ulinastatin (UTI), a clinical drug typically used for inflammatory conditions like acute pancreatitis, to inhibit NPC metastasis. By targeting the uPA/uPAR signaling pathway, UTI may offer a safer alternative or supplemental therapy to prevent the spread of cancer cells to lymph nodes and distant organs.

Methodology

The researchers employed a multi-tiered experimental design using both in vitro and in vivo models to evaluate the efficacy of UTI:

  • Cellular Assays: Highly metastatic NPC cell lines (S18 and 5-8F) were treated with varying concentrations of UTI. MTS assays were used to evaluate cell proliferation, while Transwell and wound-healing assays measured migration and invasive capacity.
  • Animal Models: To simulate clinical progression, a spontaneous footpad-to-popliteal lymph node (LN) metastasis model was established in nude mice using luciferase-expressing S18 cells. Metastatic inhibition was quantified via bioluminescence imaging and qPCR for luciferase mRNA.
  • Validation Model: The anti-metastatic effects were further validated in a breast cancer model (MMTV-PyMT mice) to assess the drug's broader applicability across different cancer types.
  • Molecular Analysis: The expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and markers of the Epithelial-to-Mesenchymal Transition (EMT) were analyzed using qPCR and Western Blotting (immunoblotting).

Results

Selective Inhibition of Migration and Invasion

In vitro results demonstrated that UTI significantly inhibited the migration and invasion of S18 and 5-8F cells in a dose-dependent manner. Crucially, this effect occurred without affecting cellular growth or viability. This suggests that UTI specifically targets the cellular machinery required for movement rather than acting as a traditional cytotoxic agent that kills cells indiscriminately, potentially offering a much lower toxicity profile than standard chemotherapy.

Suppression of Lymph Node and Lung Metastasis

In the in vivo NPC mouse model, UTI treatment led to a dramatic reduction in the spread of cancer cells. The lymph node metastasis rate dropped from 69% in the control group to just 29% in the UTI-treated group. Similar results were observed in the breast cancer validation model, where UTI significantly reduced the number of metastatic nodules in the lungs.

Safety and Tolerability

A key finding was the drug's safety profile. Mice in the UTI-treated group showed no significant loss in body weight compared to the control group, indicating that the dosage required to inhibit metastasis was well-tolerated and non-toxic.

Molecular Mechanism: Breaking the "Drill"

Molecular analysis revealed that UTI treatment led to a significant decrease in the expression of both uPA and uPAR. Cancer cells typically use the uPA/uPAR system as a "chemical drill" to degrade the extracellular matrix (the "glue" between cells), allowing them to escape the primary tumor. By downregulating these proteins, UTI effectively keeps the cancer cells in place. Additionally, UTI was found to inhibit EMT, maintaining cells in a stationary "epithelial" state and preventing them from transforming into mobile "mesenchymal" cells.

Discussion

The findings suggest that UTI acts as a potent anti-metastatic agent by disrupting the uPA/uPAR signaling axis. One intriguing observation was the "STAT3 Paradox": UTI treatment unexpectedly increased the levels of phosphorylated STAT3, a protein often linked to cancer progression. However, the use of a STAT3 inhibitor reversed UTI's beneficial effects, suggesting a complex regulatory feedback loop where the cell might be trying to compensate for the drug's inhibitory pressure. This indicates that while UTI is effective, the cellular response involves intricate signaling pathways that require further investigation to ensure long-term efficacy.

Conclusion

Ulinastatin effectively inhibits the metastasis of Nasopharyngeal Carcinoma by downregulating the uPA/uPAR pathway and suppressing EMT. Given its established safety profile and current clinical use for other conditions, UTI represents a promising candidate for repurposing as a non-toxic therapy to prevent distant metastasis in NPC patients. Future clinical trials are necessary to confirm these findings in human populations.

Summary updated

Abstract

<title>Abstract</title> <bold>Background:</bold> Distant metastasis is the main reason for treatment failure in patients with nasopharyngeal carcinoma (NPC). In this study, we evaluated the effect of ulinastatin (UTI) on NPC metastasis and investigated its underlying mechanism.<bold>Methods:</bold> Highly-metastatic NPC cell lines S18 and 5-8F were treated with UTI and the effect on cellular growth, migration, and invasion of NPC cells was determined using MTS and transwell assays. The luciferase-expressing S18 cells (S18-1C3) were injected into the left hind footpad of nude mice to establish a spontaneous footpad to popliteal lymph node (LN) metastasis model. The luciferase mRNA was measured by qPCR to calculate the metastatic inhibition rate. The UTI-related uPA, uPAR and the main molecular members of the JAT/STAT3 pathway were detected by qPCR and immunoblotting.<bold>Results</bold>: UTI inhibited the migration and invasion of S18 and 5-8F cells with no effect on cellular growth <italic>in vitro</italic>, and suppressed metastasis of S18 cells <italic>in vivo</italic>. uPAR expression was reduced from 24 to 48 hours after UTI treatment. The anti-metastasis effect of UTI partially relies on the suppression of uPA and uPAR.<bold>Conclusion:</bold> UTI partially inhibits NPC metastasis via downregulating the expression of uPA and uPAR.
BibTeX
@inproceedings{li2021ulinastatin,
  author = {Chang‐Zhi Li and Yuanyuan Qiang and Zhi‐Jie Liu and Lisheng Zheng and Li‐Xia Peng and Yan Mei and Dong‐Fang Meng and Wenwen Wei and Dong-Wen Chen and Liang Xu and Yan‐Hong Lang and Ping Xie and Xing‐Si Peng and Ming‐Dian Wang and Lingling Guo and Dehuan Xie and Ditian Shu and Liuyan Ding and Si‐Ting Lin and Fei‐Fei Luo and Jing Wang and Shasha Li and Bi‐Jun Huang and Jindong Chen and Chao‐Nan Qian},
  title = {{Ulinastatin Inhibits Nasopharyngeal Carcinoma Metastasis by Suppressing uPA/uPAR\&amp;nbsp;Signaling}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-336886/v1},
}
Figure